Advertisement

Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px
Person › Details

Nicolas Cartier (bioMérieux S.A. (Euronext: BIM))

Cartier, Nicolas (Mérieux 201305– Corporate VP Industrial Microbiology Unit at bioMérieux before Sanofi France)

 

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Former/major organisation Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
  Group Sanofi (Group) [since May 2011]
Products Product microbial genomics
  Product 2 pharmaceutical
     

bioMérieux S.A.. (5/21/13). "Press Release: Nicolas Cartier Appointed Corporate Vice President, Industrial Microbiology Unit of bioMérieux". Marcy l’Étoile.

A major player in the field of in vitro diagnostics and world leader in industrial microbiology, bioMérieux has announced the appointment of Nicolas Cartier as Corporate Vice President, Industrial Microbiology Unit, effective starting today.

Before joining bioMérieux, Nicolas Cartier, spent most of his professional career at Sanofi. Since 2009, he has been General Manager of Sanofi France, the Group's second largest affiliate. Prior to that, he gained 10 years' international experience through various roles in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division, in Shanghai, where he headed up Sanofi China's Pharmaceutical Division and in Mexico City, where he was General Manager of Sanofi Mexico. In France, Nicolas Cartier was Chief of Staff in the office of the Chairman and CEO of Sanofi France and then Business Unit Manager.

Nicolas Cartier will be a member of bioMérieux's Management Committee, reporting directly to Jean-Luc Belingard, Chairman and CEO of bioMérieux.

"I am delighted to welcome Nicolas Cartier," said Jean-Luc Belingard. "He will successfully pilot our ambitious strategy in industrial microbiology, one of our most promising fields of specialization. His international experience and his knowledge of the pharmaceutical sector will represent valuable assets, enabling bioMérieux to meet the current challenges our customers have to face in industry in order to guarantee the safety and quality of their agrifood, pharmaceutical and cosmetic products worldwide."

With over 20 years' expertise in industrial microbiological control, bioMérieux provides diagnostic solutions for customers in the agri-food, pharmaceutical and cosmetic industries. In 2012, the Company launched a new veterinary diagnostics activity with the aim of developing solutions to combat animal diseases and zoonoses while contributing to the prudent use of antibiotics in veterinary medicine. Today, bioMérieux offers the largest microbiological control product range on the market, and industrial applications account for more than 20% of the Group's business. Over 200 employees* contribute to building the success of the Industrial Microbiology Unit, which combines research and marketing activities to ensure the competitiveness of our commercial offering and support the development of the laboratories we serve.

* full-time equivalent


About the Industrial Microbiology Unit:

bioMérieux offers the broadest range of solutions for industrial microbiological control with both
manual and automated methods to provide rapid, reliable results for the agri-food, biopharmaceutical
and cosmetic industries. This range provides solutions to cover every step of microbiological analysis,
from sample preparation through to final microorganism identification.


About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more
than 150 countries through 41 subsidiaries and a large network of distributors. In 2012, revenues
reached €1,570 million with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source
of disease and contamination to improve patient health and ensure consumer safety. Its products are
used for diagnosing infectious diseases and providing high medical value results for cancer screening
and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in
agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479).
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com.


Contacts

Investor Relations

bioMérieux
Isabelle Tongio
Tel: + 33 4 78 87 22 37
investor.relations@biomerieux.com


Media Relations

bioMérieux
Aurore Sergeant
Tel: + 33 4 78 87 54 75
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr
Claire Doligez
Tel: + 33 1 53 70 74 48
cdoligez@image7.fr

   
Record changed: 2019-02-10

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px


More documents for Nicolas Cartier


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px




» top